Acumen Pharmaceuticals (ABOS) EBITDA (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted EBITDA of -$21.1 million for Q1 2026, up 16.07% sequentially from -$25.2 million in Q4 2025, and up 30.36% YoY from -$16.2 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) EBITDA (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported EBITDA for 7 years, with the latest figure at -$21.1 million in Q1 2026.
- Quarterly EBITDA rose 30.36% year-over-year to -$21.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.6 million (up 9.48% YoY) and the FY2025 annual result came in at -$123.8 million, down 8.61% from the prior year.
- EBITDA climbed to -$21.1 million in Q1 2026 per ABOS's latest filing, from -$25.2 million in the prior quarter.
- Over five years, EBITDA peaked at -$9.2 million in Q1 2022 and troughed at -$41.8 million in Q2 2025.
- A 5-year average of -$21.5 million and a median of -$18.5 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA plunged 202.56% in 2022, then surged 36.36% in 2025.
- Over 5 years, EBITDA stood at -$14.2 million in 2022, then slipped by 29.74% to -$18.5 million in 2023, then slumped by 114.2% to -$39.6 million in 2024, then soared by 36.36% to -$25.2 million in 2025, then climbed by 16.07% to -$21.1 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$21.1 million, -$25.2 million, and -$26.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Acumen Pharmaceuticals | 229.03 Mn | 229.03 Mn | - | -32.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.56 Mn |
| Mar 31, 2026 | -21.15 Mn |
| Dec 31, 2025 | -25.20 Mn |
| Sep 30, 2025 | -26.51 Mn |
| Jun 30, 2025 | -41.75 Mn |
| Mar 31, 2025 | -30.37 Mn |
| Dec 31, 2024 | -39.60 Mn |
| Sep 30, 2024 | -32.27 Mn |
| Jun 30, 2024 | -24.38 Mn |
| Mar 31, 2024 | -17.77 Mn |
| Dec 31, 2023 | -18.49 Mn |
| Sep 30, 2023 | -16.04 Mn |
| Jun 30, 2023 | -13.48 Mn |
| Mar 31, 2023 | -13.14 Mn |
| Dec 31, 2022 | -14.25 Mn |
| Sep 30, 2022 | -11.37 Mn |
| Jun 30, 2022 | -10.41 Mn |
| Mar 31, 2022 | -9.21 Mn |
| Dec 31, 2021 | -8.42 Mn |
| Sep 30, 2021 | -3.94 Mn |